m6A modification: recent advances, anticancer targeted drug discovery and beyond
LJ Deng, WQ Deng, SR Fan, MF Chen, M Qi, WY Lyu… - Molecular cancer, 2022 - Springer
Abstract Abnormal N6-methyladenosine (m6A) modification is closely associated with the
occurrence, development, progression and prognosis of cancer, and aberrant m6A …
occurrence, development, progression and prognosis of cancer, and aberrant m6A …
NBR1: The archetypal selective autophagy receptor
NL Rasmussen, A Kournoutis, T Lamark… - Journal of Cell …, 2022 - rupress.org
NBR1 was discovered as an autophagy receptor not long after the first described vertebrate
autophagy receptor p62/SQSTM1. Since then, p62 has currently been mentioned in> 10,000 …
autophagy receptor p62/SQSTM1. Since then, p62 has currently been mentioned in> 10,000 …
METTL14 is required for exercise-induced cardiac hypertrophy and protects against myocardial ischemia-reperfusion injury
L Wang, J Wang, P Yu, J Feng, G Xu, X Zhao… - Nature …, 2022 - nature.com
RNA m6A modification is the most widely distributed RNA methylation and is closely related
to various pathophysiological processes. Although the benefit of regular exercise on the …
to various pathophysiological processes. Although the benefit of regular exercise on the …
Methyltransferase-like proteins in cancer biology and potential therapeutic targeting
YN Qi, Z Liu, LL Hong, P Li, ZQ Ling - Journal of Hematology & Oncology, 2023 - Springer
RNA modification has recently become a significant process of gene regulation, and the
methyltransferase-like (METTL) family of proteins plays a critical role in RNA modification …
methyltransferase-like (METTL) family of proteins plays a critical role in RNA modification …
RNA-binding proteins in regulating mRNA stability and translation: roles and mechanisms in cancer
ABSTRACT RNA-binding proteins (RBPs) are key players in cellular physiology through
posttranscriptional regulation of the expression of target RNA transcripts. By modulating the …
posttranscriptional regulation of the expression of target RNA transcripts. By modulating the …
[HTML][HTML] The role of Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs) as m6A readers in cancer
CY Sun, D Cao, BB Du, CW Chen… - International Journal of …, 2022 - ncbi.nlm.nih.gov
RNA can be modified by over 170 types of distinct chemical modifications, and the most
abundant internal modification of mRNA in eukaryotes is N6-methyladenosine (m 6 A). The …
abundant internal modification of mRNA in eukaryotes is N6-methyladenosine (m 6 A). The …
Roles of RNA modifications in diverse cellular functions
Chemical modifications of RNA molecules regulate both RNA metabolism and fate. The
deposition and function of these modifications are mediated by the actions of writer, reader …
deposition and function of these modifications are mediated by the actions of writer, reader …
METTL3 protects METTL14 from STUB1‐mediated degradation to maintain m6A homeostasis
ZC Zeng, Q Pan, YM Sun, HJ Huang, XT Chen… - EMBO …, 2023 - embopress.org
Abstract N 6‐Methyladenosine (m6A) is an important RNA modification catalyzed by
methyltransferase‐like 3 (METTL3) and METTL14. m6A homeostasis mediated by the …
methyltransferase‐like 3 (METTL3) and METTL14. m6A homeostasis mediated by the …
METTL14 promotes prostate tumorigenesis by inhibiting THBS1 via an m6A-YTHDF2-dependent mechanism
Y Wang, J Chen, WQ Gao, R Yang - Cell death discovery, 2022 - nature.com
Abstract N6-methyladenine (m6A) is the most predominant RNA modification, which has
been shown to be related to many types of cancers. However, understanding of its role in …
been shown to be related to many types of cancers. However, understanding of its role in …
METTL14 modulates glycolysis to inhibit colorectal tumorigenesis in p53‐wild‐type cells
Y Hou, X Zhang, H Yao, L Hou, Q Zhang, E Tao… - EMBO …, 2023 - embopress.org
The frequency of p53 mutations in colorectal cancer (CRC) is approximately 40–50%. A
variety of therapies are being developed to target tumors expressing mutant p53. However …
variety of therapies are being developed to target tumors expressing mutant p53. However …